United Therapeutics CFO sells shares, exercises options
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. On April 27, 2026, he exercised 10,000 stock options at $135.42 per share and sold 10,000 common shares in multiple open-market trades at weighted-average prices around $565–$572, under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 common shares and 52,500 stock options.
Positive
- None.
Negative
- None.
Insights
CFO exercised options and sold shares under a pre-set 10b5-1 plan, a routine liquidity event.
The CFO of UNITED THERAPEUTICS Corp, James Edgemond, exercised 10,000 stock options at an exercise price of $135.42 and sold 10,000 common shares in open-market trades on April 27, 2026. These trades were executed at weighted-average prices around $565–$572.
A footnote states the exercise and subsequent sales were made under a Rule 10b5-1 trading plan adopted on October 31, 2025, indicating the timing was pre-arranged. Following the transactions, he holds 18,876 shares directly plus 52,500 remaining stock options, so this appears to be a planned, partial monetization rather than a full exit.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.33M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.69M)
Approx. gross sale proceeds
$5.69M
Approx. exercise cost
$1.35M
Approx. pre-tax spread
$4.33M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 1,716 | $565.8482 | $971K |
| Sale | Common Stock | 1,449 | $566.7294 | $821K |
| Sale | Common Stock | 919 | $567.8146 | $522K |
| Sale | Common Stock | 1,107 | $569.0148 | $630K |
| Sale | Common Stock | 2,405 | $570.0465 | $1.37M |
| Sale | Common Stock | 1,755 | $571.0959 | $1.00M |
| Sale | Common Stock | 649 | $571.9205 | $371K |
Holdings After Transaction:
Stock Option — 52,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (8)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $565.22 to $566.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $566.36 to $567.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $567.41 to $568.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $568.55 to $569.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $569.59 to $570.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $570.62 to $571.605. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $571.62 to $572.415. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Options exercised: 10,000 options
Exercise price: $135.42 per share
+5 more
8 metrics
Shares sold
10,000 shares
Net common shares sold on April 27, 2026
Options exercised
10,000 options
Stock options converted into common shares
Exercise price
$135.42 per share
Strike price of exercised stock options
Sale price range
$565.22–$572.415 per share
Weighted-average trade ranges from multiple executions
Shares held after
18,876 shares
Direct common stock ownership after transactions
Options remaining
52,500 options
Stock options outstanding following the exercise
Option expiration
March 15, 2027
Expiration date of the exercised option grant
Net share direction
10,000-share net sale
transactionSummary netBuySellShares
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond do in this Form 4 filing?
CFO James Edgemond exercised 10,000 stock options and sold 10,000 United Therapeutics common shares. The options had a $135.42 exercise price, and the sales occurred around $565–$572 per share, reflecting a planned liquidity event disclosed in the Form 4.
What stock options remain for the United Therapeutics (UTHR) CFO after this Form 4?
Following the exercise of 10,000 stock options, the CFO still holds 52,500 stock options. The exercised options carried a $135.42 exercise price and an expiration date of March 15, 2027, while the remaining options continue to represent potential future share acquisitions.
Is the United Therapeutics (UTHR) CFO’s transaction mainly a sale or an exercise?
The filing shows a combined pattern: exercising 10,000 stock options and selling 10,000 common shares. Aggregate data indicate a net sale of 10,000 shares, paired with continued holdings of 18,876 shares and 52,500 options, suggesting ongoing equity exposure for the executive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
